DETERMINANTS OF LIPID-LEVELS AMONG CHILDREN WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN NORWAY

被引:36
|
作者
TONSTAD, S [1 ]
LEREN, TP [1 ]
SIVERTSEN, M [1 ]
OSE, L [1 ]
机构
[1] UNIV OSLO, ULLEVAAL HOSP, DEPT MED GENET, N-0407 OSLO, NORWAY
关键词
FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR MUTATION; APO E; DIETARY INTAKE; CHILDREN;
D O I
10.1161/01.ATV.15.8.1009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three founder mutations have been discovered among individuals with familial hypercholesterolemia (FH) in Norway: FHElverum and FHSvartor, predicted to be null alleles, and FHC210G, predicted to disrupt the secondary structure of the ligand-binding domain. To clarify the effect of these and other mutations on lipid levels and parental history of premature cardiovascular disease, we examined 164 boys and girls ages 6 to 16 years with heterozygous FH. Among all children, serum cholesterol levels of the FH parent, percent body fat, pubertal stage, and serum cholesterol levels of the non-FH parent, but not apo E polymorphism, were significant determinants of LDL cholesterol levels in a stepwise multiple regression equation and explained 40% (95% confidence interval [CI], 25% to 55%) of the variance in LDL cholesterol. Among boys, percent body fat, dietary sucrose, and apo E genotype determined 31% (95% CI, 14% to 49%) of the variance in triglyceride levels; whereas among girls, only percent body fat was associated with triglyceride levels. Percent body fat was not associated with LDL cholesterol or triglyceride levels in the FHC210G group. The children's and FH parents' lipid levels and premature cardiovascular disease among parents were similar among the nullallele and defective-protein groups and in those with an undetected mutation. These data confirm that the phenotypic expression of FH in childhood is influenced by modifiable lifestyle characteristics and by genetic factors other than the underlying mutation and raise the possibility that body fatness may interact with genotype in determining lipid levels.
引用
收藏
页码:1009 / 1014
页数:6
相关论文
共 50 条
  • [31] SERUM-LIPID AND LIPOPROTEIN LEVELS IN JAPANESE PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    MABUCHI, H
    TATAMI, R
    UEDA, K
    UEDA, R
    HABA, T
    KAMETANI, T
    WATANABE, A
    WAKASUGI, T
    ITO, S
    KOIZUMI, J
    OHTA, M
    MIYAMOTO, S
    TAKEDA, R
    ATHEROSCLEROSIS, 1979, 32 (04) : 435 - 444
  • [32] Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia
    Larivière, M
    Lamarche, B
    Pirro, M
    Hogue, JC
    Bergeron, J
    Gagné, C
    Couture, P
    ATHEROSCLEROSIS, 2003, 167 (01) : 97 - 104
  • [33] Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
    Hartgers, Merel L.
    Besseling, Joost
    Stroes, Erik S.
    Wittekoek, Janneke
    Rutten, Joost H. W.
    de Graaf, Jacqueline
    Visseren, Frank L. J.
    Imholz, Ben P. M.
    van Lennep, Jeanine E. Roeters
    Huijgen, Roeland
    Kastelein, John J. P.
    Hovingh, G. Kees
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 972 - 980
  • [34] Familial Hypercholesterolemia in Children and Safety of Early Lipid-Lowering Treatment
    Bellunghi, Maria Sol
    Miname, Marcio
    Jannes, Cinthia E.
    Silva, Pamela R.
    Pereira, Alexandre
    Chacra, Ana Paula
    Salgado, Wilson
    Santos, Raul D.
    Rocha, Viviane Z.
    CIRCULATION, 2017, 136
  • [35] Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia
    Lovheim, Eirin B.
    Retterstol, Kjetil
    Narverud, Ingunn
    Bogsrud, Martin P.
    Halvorsen, Bente
    Ueland, Thor
    Aukrust, Pal
    Holven, Kirsten B.
    ATHEROSCLEROSIS PLUS, 2024, 58 : 38 - 45
  • [36] Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
    Mysliwiec, Malgorzata
    Walczak, Mieczyslaw
    Malecka-Tendera, Ewa
    Dobrzanska, Anna
    Cybulska, Barbara
    Filipiak, Krzysztof
    Mazur, Artur
    Jarosz-Chobot, Przemyslawa
    Szadkowska, Agnieszka
    Rynkiewicz, Andrzej
    Chybicka, Alicja
    Socha, Piotr
    Brandt, Agnieszka
    Bautembach-Minkowska, Joanna
    Zdrojewski, Tomasz
    Limon, Janusz
    Gidding, Samuel S.
    Banach, Maciej
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (02) : 173 - 180
  • [37] Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study
    Christensen, Jacob J.
    Ulven, Stine M.
    Retterstol, Kjetil
    Narverud, Ingunn
    Bogsrud, Martin P.
    Henriksen, Tore
    Bollerslev, Jens
    Halvorsen, Bente
    Aukrust, Pal
    Holven, Kirsten B.
    ATHEROSCLEROSIS, 2017, 266 : 48 - 57
  • [38] Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic
    Johansen, Anja K.
    Bogsrud, Martin P.
    Thoresen, Magne
    Christensen, Jacob J.
    Narverud, Ingunn
    Langslet, Gisle
    Svilaas, Tone
    Retterstol, Kjetil
    Holven, Kirsten B.
    ATHEROSCLEROSIS PLUS, 2024, 57 : 13 - 18
  • [39] Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100:: the MEDPED Slovakia project
    Vohnout, B
    Raslová, K
    Gasparovic, J
    Franeková, J
    Fábryová, L
    Belosovicová, M
    Kovác, G
    Sebová, C
    Rajecová, E
    Stavny, J
    Babjak, M
    Donati, MB
    Iacoviello, L
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (03) : 3 - 5
  • [40] Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia
    Carmena-Ramón, R
    Real, JT
    Ascaso, JF
    Ordovás, JM
    Carmena, R
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2000, 10 (01) : 7 - 13